The effects of methylenedioxymethamphetamine (MDMA, 'Ecstasy') on monoaminergic neurotransmission in the central nervous system

Progress in Neurobiology

Volumn 49, Issue 5, 1996, Pages 455-479

  White, S R ^a   Obradovic, T ^a   Imel, K M ^a   Wheaton, M J ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; DOPAMINERGIC NERVE CELL; ELECTROPHYSIOLOGY; HYPERTHERMIA; LOCOMOTION; MONOAMINERGIC SYSTEM; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC NERVE CELL;

EID: 0030218082     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/0301-0082(96)00027-5     Document Type: Article

References (220)

1. Aghajanian G.K., Bunney B.S. Dopamine "autoreceptors": pharmacological characterization by microiontophoretic single unit recording studies. Neu. Schmied. Arch. Pharmacol. 297:1977;1-7.
2. Aghajanian G.D., VanderMaelen C.P. Intracellular recordings from serotonergic dorsal raphe neurons: pacemaker potentials and the effects of LSD. Brain Res. 238:1982;463-469.
3. Akaike A., Sasa M., Takaori S. Effects of haloperidol and sulpiride on dopamine-induced inhibition of nucleus accumbens neurons. Life Sci. 32:1983;2649-2653.
4. Apicella P., Ljungberg T., Scarnati E., Schultz W. Responses to reward in monkey dorsal and ventral striatum. Expl Brain Res. 85:1991;491-500.
5. Azmitia E.C., Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 179:1978;641-668.
6. 2 receptors in the rat nucleus accumbens: resistance to differential rearing conditions. Neuroscience. 45:1991;281-290.
7. 3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology. 29:1990;1037-1045.
8. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylene-dioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 149:1988;159-163.
9. Battaglia G., Sharkey J., Kuhar M.J., De Souza E.B. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylene-dioxymethamphetamine): assessment using quantitative autoradiography (1991). Synapse. 8:1991;249-260.
10. Bayliss D.A., Umemiya M., Berger A.J. Inhibition of N- and P-type calcium currents and the afterhyperpolarization in rat motoneurons by serotonin. J. Physiol. Lond. 485:1995;635-647.
11. Beardsley P.M., Balster R.L., Harris L.S. Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys. Drug Alc. Dep. 18:1986;149-157.
12. Benloucif S., Galloway M.P. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur. J. Pharmacol. 200:1991;1-8.
13. Berger U.V., Gu X.F., Azmitia E.C. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 215:1992;153-160.
14. Bjorklund, A. and Lindvall, O. (1984) Dopamine-containing systems in the CNS. In: Handbook of Chemical Neuroanatomy, Vol. 2. Classical Transmitters in the CNS, pp. 55-122. Eds A. Bjorklund and T. Hokfelt. Elsevier: NY.
15. 3 receptors in rat striatum. J. Pharmacol. Expl Ther. 251:1989;803-809.
16. Boeijinga P.H., Pennartz C.M.A., Lopes da Silva F.H. Paired-pulse facilitation in the nucleus accumbens following stimulation of subicular inputs in the rat. Neuroscience. 35:1990;301-311.
17. 125I]-iodosulpride. Synapse. 19:1995;1-13.
18. Bradberry C.W., Sprouse J.S., Sheldon P.W., Aghjanian G.K., Roth R.H. In vitro microdialysis: a novel technique for stimulated neurotransmitter release measurements. J. Neurosci. Meth. 36:1991;85-90.
19. Brodie M.S., Bunney E.B. Serotonin enhances dopamine-induced inhibition of ventral tegmental area (VTA) neurons recorded in vitro. Soc. Neurosci. Abstr. 20:1994;1553.
20. Brodkin J., Malyala A., Nash J.F. Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol. Biochem. Behav. 45:1993;647-653.
21. Brog J.S., Salyapongse A., Deutch A.Y., Zahm D.S. The patterns of afferent innervation of the core and shell in the "accumbens" part of the rat ventral striatum: immunohistochemical detection of retrogradely transported fluoro-gold. J. Comp. Neurol. 338:1993;255-278.
22. 1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 33:1994;367-386.
23. Bunney B.S., Walters J.R., Roth R.H., Aghajanian G.K. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J. Pharmacol. Expl Ther. 185:1973;560-571.
24. Cadet J.L., Landenheim B.L., Hirata H., Rothman R.B., Ali S., Carlson E., Epstein C., Moran T.H. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse. 21:1995;169-176.
25. Callaway C.W., Geyer M.A. Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat. Eur. J. Pharmacol. 214:1992;45-51.
26. Callaway C.W., Wing L., Geyer M.A. Serotonin release contributes to the stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J. Pharmacol. Expl Ther. 254:1990;456-464.
27. 1 receptors facilitate transmitter release. Nature (Lond.). 366:1993;344-347.
28. Cameron D.L., Williams J.T. Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J. Neurosci. 14:1994;6763-6767.
29. Carelli R.M., Deadwyler S.A. A comparison of nucleus accumbens neuronal firing patterns during cocaine self-administration and water reinforcement in rats. J. Neurosci. 14:1994;7735-7746.
30. Carter C.J. Topographical distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats. Neuropharmacology. 21:1982;379-383.
31. Chang H.T., Kitai S.T. Projection neurons of the nucleus accumbens: an intracellular labeling study. Brain Res. 347:1985;112-116.
32. Chang J-Y., Sawyer F., Lee R-S., Woodward D.J. Electrophysiological and pharmacological evidence for the role of the nucleus accumbens in cocaine self-administration in freely moving rats. J. Neurosci. 14:1994;1224-1244.
33. Chipkin R.E., Iorie L.C., Coffin V.L., McQuade R.D., Berger J.G., Barnett A. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J. Pharmacol. Expl Ther. 247:1988;1093-1102.
34. Christie M.F., Bridge S., James L.B., Beart P.M. Excitotoxin lesions suggest an aspartatergic projection from rat medial prefrontal cortex to ventral tegmental area. Acta Physiol. Scand. 136:1989;135-136.
35. Colado M.E., Murray T.K., Green A.R. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol. 108:1993;583-589.
36. Commins D.L., Vosmer G., Virus R.M., Woolverton W.L., Schuster C.R., Seiden L.S. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Expl Ther. 241:1987;338-345.
37. Cregg M.T., Tracey J.A. Ecstasy abuse in Ireland. Ir. Med. J. 86:1993;118-120.
38. Creighton F.J., Black D.L., Hyde C.E. Ecstasy psychosis and flashbacks. Br. J. Psychol. 159:1991;713-715.
39. Crossman A.R., Walker R.J., Woodruff G.N. Pharmacological studies on single neurons in the substantia nigra of the rat. Br. J. Pharmacol. Chemother. 51:1974;137-138.
40. Cuomo M.J., Dyment P.G., Gammino V.M. Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus. J. Am. Coll. Health. 42:1994;271-274.
41. Dackis C.A., Gold M.S. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci. Biobehav. Rev. 9:1985;469-477.
42. Deutsch A.Y., Cameron D.S. Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience. 46:1992;49-56.
43. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA. 85:1988;5274-5278.
44. Dray a., Gonye T.J., Oakley N.R., Tanner T. Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res. 113:1976;45-57.
45. Dykhuizen R.S., Brunt P.W., Atkinson P., Simpson J.G., Smith C.C. Ecstasy induced hepatitis mimicking viral hepatitis. Gut. 36:1995;939-941.
46. Farfel G.M., Seiden L.S. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX J. Pharmacol. Expl Ther. 272:1995;860-867.
47. Farfel G.M., Vosmer G.L., Seiden L.S. The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4,-methylenedioxymethamphetamine and p-chloramphetamine. Brain Res. 595:1992;121-127.
48. Fischer C., Hatzidimitriou G., Wlos J., Katz J., Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J. Neurosci. 15:1995;5476-5485.
49. Fitzgerald J.L., Reid J.J. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur. J. Pharmacol. 191:1990;217-220.
50. Fuller T.A., Russchen F.T., Price J.L. Sources of presumptive glutamergic/aspartergic afferents to the rat ventral striatopallidal region. J. Comp. Neurol. 258:1987;317-338.
51. Galloway M.P., Suchowski C.S., Keegan M.J., Hjorth S. Local infusion of the selective 5HT-1b agonist CP-93,129 facilitates striatal dopamine release in vivo. Synapse. 15:1993;90-92.
52. Garris P.A., Ciolkowski E.L., Pastore P., Wightman R.M. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J. Neurosci. 14:1994;6084-6093.
53. Gawin F.H. Cocaine addiction: psychology and neurophysiology. Science. 251:1991;1580-1586.
54. Gold L.H., Koob G.F., Geyer M.A. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J. Pharmacol. Expl Ther. 247:1988;547-555.
55. Gough B., Ali S.F., Slikker W., Holson R.R. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol. Biochem. Behav. 39:1991;619-623.
56. Grace A.A., Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons. I. Identification and characterization Neuroscience. 10:1983;301-315.
57. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology. 119:1995;247-260.
58. Groenewegen H.J., Russchen F.T. Organization of the efferent projections of the nucleus accumbens to pallidal, hypothalamic and mesencephalic structures: a tracing and immunohistochemical study in the cat. J. Comp. Neurol. 223:1984;347-367.
59. Groenewegen, H.J., Berendse, H.W., Wolters, J.G. and Lohman, A.H.M. (1990) The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus and the amygdala: evidence for a parallel organization. In: Progress in Brain Research, Vol. 85, pp. 95-118. Eds H.B.M. Uylings, C.G. VanEden, J.P.C. DeBruin, M.A. Corner and M.G.P. Feenstra. Elsevier: Amsterdam.
60. Gu X.F., Azmitia E.C. Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur. J. Pharmacol. 235:1993;51-57.
61. Guan X-M., McBride W.J. Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res. Bull. 23:1989;541-547.
62. Gudelsky G.A., Yamamoto B.K., Naxh J.F. Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur. J. Pharmacol. 264:1994;325-330.
63. 1 receptors. Neuropharmacology. 28:1989;1203-1209.
64. Hekmatpanah C.R., Peroutka S.J. 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine releasing effects of 3,4-methylenedioxymethamphetamine and related agent. Eur. J. Pharmacol. 177:1990;95-98.
65. Heimer L., Zahm D.S., Churchill L., Kalivas P.W., Wohltmann C. Specificity in the projection patterns of the accumbal core and shell in the rat. Neuroscience. 41:1991;89-125.
66. 1 dopamine receptor sensitivity within the rat nucleus accumbens. J. Pharmacol. Expl Ther. 258:1991;882-890.
67. Hernandez L., Hoebel B.G. Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sci. 42:1988;1705-1712.
68. Hernandez L., Lee F., Hoebel B.G. Simultaneous microdialysis and amphetamine infusion in the nucleus accumbens and striatum of freely moving rats: increase in extracellular dopamine and serotonin. Brain Res. Bull. 19:1987;623-628.
69. Herve K., Pickel V.M., Joh T.H., Beaudet A. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435:1987;71-83.
70. Higashi H., Inanaga K., Nishi S., Uchimura N. Enhancement of dopamine actions on rat nucleus accumbens neurones in vitro after methamphetamine pretreatment. J. Physiol. (Lond.). 408:1989;587-603.
71. Hokfelt T., Rehfeld J.F., Skirboll L., Ivemark B., Goldstein M., Marley K. Evidence for coexistence of dopamine and cholecystokinin in mesolimbic neurons. Nature (Lond.). 285:1980;476-478.
72. Hsu, K.-S. (1996) Characterization of dopamine receptors mediating inhibition of excitatory synaptic transmission in the rat hippocampal slice. J. Neurophysiol. (in press).
73. Hu X-T., Wang R.Y. Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study. J. Neurosci. 8:1988;4340-4348.
74. 2 receptor selective antagonists: electrophysiological and behavioral studies. Synapse. 17:1994;43-61.
75. Jackson D.A., White S.R. Receptor subtypes mediating facilitation by serotonin of excitability of spinal motoneurons. Neuropharmacology. 29:1990;787-797.
76. Jacocks H.M., Cox B.M. Serotonin-stimulated release of [3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: A comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J. Pharmacol. Expl Ther. 262:1992;356-364.
77. 3H-BIMU-1. Neuropharmacology. 33:1994;1027-1038.
78. Johnson S.W., North R.A. Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J. Physiol. (Lond.). 450:1992;455-468.
79. 3H-dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132:1986;269-276.
80. Johnson M.P., Conarty P.F., Nichols D.E. [3H] monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur. J. Pharmacol. 200:1991;9-16.
81. Johnson M., Bush L.G., Gibb J.W., Hanson G.R. Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in neurotensin and dynorphin A systems. Eur. J. Pharmacol. 193:1991;367-370.
82. B synaptic potential in rat dopamine neurons. J. Neurosci. 12:1992;2000-2006.
83. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18:1993;75-113.
84. Kalivas P.W., Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse. 5:1990;48-58.
85. Kalivas P.W., Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals J. Neurosci. 13:1993;266-275.
86. Katakura N., Chandler S.H. An iontophoretic analysis of the pharmacologic mechanisms responsible for trigeminal motoneuronal discharge during masticatory-like activity in the guinea pig. J. Neurophysiol. 63:1990;356-369.
87. Kelland M.D., Freeman A.S., Chiodo L.A. (±)-3,4-Methylenedioxymethamphetamine-induced changes in the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons. Eur. J. Pharmacol. 169:1989;11-21.
88. Kelland M.D., Freeman A.S., Chiodo L.A. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J. Pharmacol. Expl Ther. 253:1990;803-811.
89. Khakoo S.I., Coles C.J., Armstrong J.S., Barry R.E. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymethamphetamine ("Ecstasy") usage. J. Clin. Gastroenterol. 20:1995;244-247.
90. 1A receptor antagonist. Brain Res. 673:1995;217-225.
91. 3 receptors in the rat brain using radioligand binding. Nature. 330:1987;746-748.
92. Kleven M.S., Woolverton W.L., Seiden L.S. Lack of long-term monoamine depletions following repeated or continuous exposure to cocaine. Brain Res. Bull. 21:1988;233-237.
93. Kokotos Leonardi E.T., Azmitia E.C. MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology. 10:1994;231-238.
94. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
95. Kosofsky B.E., Molliver M.E. The serotoninergic innervation of cerebral cortex: different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse. 1:1987;153-168.
96. Kubin L., Tojima H., Davies R.O., Pack A.I. Serotonergic excitatory drive to hypoglossal motoneurons in the decerebrate cat. Neurosci. Lett. 139:1992;243-248.
97. Lacey M.G., Mercuri N.B., North R.A. Actions of cocaine on rat dopaminergic neurones in vitro. Br. J. Pharmacol. 99:1990;731-735.
98. Lamb R.J., Griffiths R.R. Self-injection of 3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology. 91:1987;268-272.
99. Larkman P.M., Kelly J.S. Ionic mechanisms mediating 5-hydroxytryptamine- and noradrenaline-evoked depolarization of adult rat facial motoneurones. J. Physiol. (Lond.). 456:1992;473-490.
100. Li A.A., Marek G.J., Vosmer G., Seiden L.S. Long-term central 5-HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of MDMA on schedule-controlled behavior of rats. Pharmacol. Biochem. Behav. 33:1989;641-648.
101. Logan B.J., Laverty R., Sanderson W.D., Yee Y.B. Differences between rats and mice in MDMA (methylenedioxymethamphetamine) neurotoxicity. Eur. J. Pharmacol. 152:1988;227-234.
102. Lorens S.A., Guldberg H.C. Regional 5-hydroxytryptamine following selective midbrain raphe lesions in the rat. Brain Res. 78:1974;45-56.
103. Mamounas L.A., Mullen C.A., O'Hearn E., Molliver M.E. Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J. Comp. Neurol. 314:1991;558-586.
104. 1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience. 46:1992;959-971.
105. Marshall F.H., Barnes S., Hughes J., Woodruff G.N., Hunter J.C. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J. Neurochem. 56:1991;917-922.
106. Martin G.R., Humphrey P.P.A. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology. 33:1994;261-273.
107. Matthews R.T., Champney T.H., Frye G.D. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on brain dopaminergic activity in rats. Pharmacol. Biochem. Behav. 33:1989;741-747.
108. McCall R.B., Aghajanian G.K. Serotoninergic facilitation of facial motoneuron excitation. Brain Res. 169:1979;11-27.
109. McCann U.D., Ricaurte G.A. Lasting neuropsychiatric sequelae of (±) methylenedioxymethamphetamine ("Ecstasy") in recreational users. J. Clin. Psychopharmacol. 11:1991;302-305.
110. McCann U.D., Ridenour A., Shaham Y., Ricaurte G.A. Serotonin neurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology. 10:1994;129-138.
111. McGuire P.K., Cope H., Fahy T.A. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ("Ecstasy"). Br. J. Psychol. 165:1994;391-395.
112. McKenna D.J., Peroutka S.J. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J. Neurochem. 54:1990;14-22.
113. 3H-5-hydroxytryptamine. Pharmacol. Biochem. Behav. 38:1991;505-512.
114. McNamara M.G., Kelly J.P., Leonard B.E. Some behavioural and neurochemical aspects of subacute (±)3,4-methylenedioxymethamphetamine administration in rats. Pharmacol. Biochem. Behav. 52:1995;479-484.
115. Mengod G., Nguyen H., Le H., Waeber C., Lubbert H., Palacios J.M. The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry: comparison with receptor binding distribution. Neuroscience. 35:1990;577-591.
116. 2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 524:1990;139-143.
117. Meredith G.E., Blank B., Groenewegen H.J. The distribution and compartmental organization of the cholinergic neurons in the nucleus accumbens of the rat. Neuroscience. 31:1989;327-345.
118. Meredith G.E., Agolia R., Arts M., Groenewegen H.J., Zahm D.S. Morphological differences between the projection neurons in the core and shell of the nucleus accumbens in the rat. Neuroscience. 50:1992;149-162.
119. Miller J.J., Richardson T.L., Fibiger H.C., McLennan H. Anatomical and electrophysiological identification of a projection from the mesencephalic raphe to the caudate putamen in the rat. Brain Res. 97:1975;133-138.
120. Mugnaini, E. and Oertel, W.H. (1985) An atlas of the distribution of GABAergic neurons and terminals in the rat CNS as revealed by GAD immunohistochemistry. In: Handbook of Neuroanatomy, Vol. 4, pp. 436-608. Eds A. Bjorklund and T. Hokfelt. Elsevier: Amsterdam.
121. Nash J.F. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 47:1990;2401-2408.
122. Nash J.F., Brodkin J. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Expl Ther. 259:1991;820-825.
123. Nash J.F., Yamamoto B.K. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581:1992;237-243.
124. Nash J.F., Meltzer H.Y., Gudelsky G.A. Elevation of serum prolactin and corticosterone concentrations after administration of 3,4-methylenedioxymethamphetamine. J. Pharmacol. Expl Ther. 245:1988;873-879.
125. 2C receptors. Neurosci. Lett. 177:1994;111-115.
126. 3H]-serotonin from rat brain synaptosomes. J. Med. Chem. 25:1982;530-535.
127. Nicola S.M., Kombian S.B., Malenka R.C. Psychostimulants depress excitatory synaptic transmission in the nucleus accumbens via presynaptic D1-like dopamine receptors. J. Neurosci. 16:1996;1591-1604.
128. 2 receptors to decrease potassium conductance in rat nucleus accumbens neurones. J. Physiol. (Lond.). 417:1989;1-12.
129. Oades R.D., Halliday G.M. Ventral tegmental (A10) system: neurobiology, anatomy and connectivity. Brain Res. Rev. 12:1987;117-165.
130. Obradovic T., Imel K.M., White S.R. Differential effects of methylenedioxymethamphetamine (MDMA) in the nucleus accumbens core and shell. Soc. Neurosci. Abstr. 21:1995;970.
131. Obradovic, T., Imel, K.M. and White, S.R. (1996) Methylene-dioxymethamphetamine-induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine receptors. Neuroscience (in press).
132. O'Connor B. Hazards associated with the recreational drug `Ecstasy'. Br. J. Hosp. Med. 52:1994;507-514.
133. O'Hearn E., Battaglia G., DeSouza E.B., Kuhar M.J., Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 8:1988;2788-2803.
134. Olpe H., Koella W.P. The response of striatal cells upon stimulation of the dorsal and median raphe nuclei. Brain Res. 122:1977;357-360.
135. Pallanti S., Mazzi D. MDMA (ecstasy) precipitation of panic disorder. Biol. Psychiat. 32:1992;91-95.
136. Pan H.S., Wang R.Y. The action of (±)-MDMA on medial prefrontal cortical neurons is mediated through the serotonergic system. Brain Res. 543:1991;56-60.
137. Pan H.S., Wang R.Y. MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system. Brain Res. 539:1991;332-336.
138. Paris J.M., Cunningham K.A. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res. Bull. 28:1992;115-119.
139. Parkis M.A., Bayliss D.A., Berger A.J. Actions of norepinephrine on hypoglossal motoneurons. J. Neurophysiol. 74:1995;1911-1919.
140. Parsons L.H., Justice J.B. Jr. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res. 606:1993;195-199.
141. Parsons L.H., Justice J.B. Jr. Serotonin and dopamine sensitization in the nucleus accumbens, ventral tegmental area and dorsal raphe nucleus following repeated cocaine administration. J. Neurochem. 61:1993;1611-1619.
142. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Plenum: NY.
143. Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors Brain Res. 346:1985;205-230.
144. Pazos A., Cortes R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors Brain Res. 346:1985;231-249.
145. Pennartz C.M.A., Kitai S.T. Hippocampal inputs to identified neurons in an in vitro slice preparation of the rat nucleus accumbens: evidence for feed-forward inhibition. J. Neurosci. 11:1991;2838-2847.
146. 1 receptors attenuate excitatory and inhibitory limbic inputs to the shell region of the rat nucleus accumbens studied in vitro. J. Neurophysiol. 67:1992;1325-1334.
147. Pennartz C.M.A., Groenewegen H.J., Lopes Da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural electrophysiological and anatomical data. Progr. Neurobiol. 42:1994;719-761.
148. Pickel V.M., Towle A.C., Joh T.H., Chan J. γ-Aminobutyric acid in the medial rat nucleus accumbens: ultrastructural localization in neurons receiving monosynaptic input from catecholaminergic afferents. J. Comp. Neurol. 272:1988;1-14.
149. Pierce R.C., Kalivas P.W. Amphetamine produces sensitized increases in locomotion and extracellular dopamine preferentially in the nucleus accumbens shell of rats administered repeated cocaine. J. Pharmacol. Expl Ther. 275:1995;1019-1029.
150. Poblete J.C., Azmitia E.C. Activation of glycogen phosphorylase by serotonin and 3,4-methylenedioxymethamphetamine in astroglial-rich primary cultures: involvement of the 5-HT2A receptor. Brain Res. 680:1995;9-15.
151. 2C receptors. Mol. Brain Res. 23:1994;163-178.
152. Premkumar L.S., Ahern G.P. Blockade of a resting potassium channel and modulation of synaptic transmission by Ecstasy in the hippocampus. J. Pharmacol. Expl Ther. 274:1995;718-722.
153. B agonists and serotonin in cultured hippocampal neurons. J. Neurophysiol. 71:1994;2570-2575.
154. Randall J. Ecstasy-fueled "rave" parties become dances of death for English youths. JAMA. 268:1992;1505-1506.
155. 1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology. 8:1993;201-211.
156. Ricaurte G.A., McCann U.D. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann. NY Acad. Sci. 648:1992;371-382.
157. Ricaurte G.A., Bryan G., Strauss L., Seiden L., Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science. 229:1985;986-988.
158. Ricaurte G.A., Forno L.S., Wilson M.A., DeLanney L.E., Irwin I., Molliver M.E., Langston J.W. 3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 260:1988;51-55.
159. Ricaurte G.A., Finnegan K.T., Irwin I., Langston J.W. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann. NY Acad. Sci. 600:1990;699-710.
160. Roberts D.C.S., Koob G.F., Klonoff P., Fibiger H.C. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 12:1980;781-787.
161. Rolls, E.T. and Williams, G.V. (1988) Neuronal activity in the ventral striatum of the primate. In: Basal Ganglia II, Advances in Behavioral Biology, Vol. 32, pp. 349-356. Eds M.B. Carpenter and A. Jayamaran. Plenum: London.
162. 6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 193:1993;268-276.
163. Rudnick, G. and Wall, S.C. (1992) The molecular mechanism of "Ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.
164. Scanzello C.R., Hatzidimitriou G., Martello A.L., Katz J.L., Ricaurte G.A. Serotonergic recovery after (±)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J. Pharmacol. Expl Ther. 264:1993;1484-1491.
165. Scheffel U., Lever J.R., Stathis M., Ricaurte G.A. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology. 31:1992;881-893.
166. Schifano F., Magni G. MDMA ("Ecstasy") abuse: psychopathological features and craving for chocolate: a case series. Biol. Psychiat. 36:1994;763-767.
167. Schmidt C.J., Levin J.A., Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol. 36:1987;747-755.
168. Schmidt C.J., Black C.K., Abbate G.M., Taylor V.L. Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 529:1990;85-90.
169. Schmidt C.J., Taylor V.L., Abbate G.M., Nieduzak T.R. 5-HT2 Antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-Dopa. J. Pharmacol. Expl Ther. 256:1991;230-235.
170. 2 receptors reduces the increase in extracellular concentrations of dopamine produced by amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62:1994;1382-1389.
171. Sharkey J., McBean D.E., Kelly P.A.T. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy"). Psychopharmacology. 105:1991;113-118.
172. Schultz W., Apicella P., Scarnati E., Ljungberg T. Neuronal activity in monkey ventral striatum related to the expectation of reward. J. Neurosci. 12:1992;4595-4610.
173. Smith D.O., Lowe D., Temkin R., Jensen P., Hatt H. Dopamine enhances glutamate-activated currents in spinal motoneurons. J. Neurosci. 15:1995;3905-3912.
174. Sprague J.E., Huang X., Kanthasamy A., Nichols D.E. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci. 55:1994;1193-1198.
175. Sprague J.E., Nichols D.E. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Expl Ther. 273:1995;667-673.
176. Sprouse J.S., Bradberry C.W., Roth R.H., Aghajanian G.K. MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin. Eur. J. Pharmacol. 167:1989;375-383.
177. Sprouse J.S., Bradberry C.W., Roth R.H., Aghajanian G.K. 3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan. Eur. J. Pharmacol. 178:1990;313-320.
178. Steele T.D., Nichols D.E., Yim G.K.W. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]-monoamines into synaptosomes from different regions of rat brain. Biochem. Pharmacol. 36:1987;2297-2303.
179. Steele T.D., McCann U.D., Ricaurte G.A. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction. 89:1994;539-551.
180. Steinbusch H.W.M. Distribution of serotonin-immunoreactivity in the central nervous system of the rat: cell bodies and terminals. Neuroscience. 6:1981;557-618.
181. Stone D.M., Hanson G.R., Gibb J.W. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology. 26:1987;1657-1661.
182. Stone D.M., Johnson M., Hanson G.R., Gibb J.W. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Expl Ther. 247:1988;79-87.
183. Suppes T., Kriegstein A., Prince D.A. The influence of dopamine on epileptiform burst activity in hippocampal pyramidal neurons. Brain Res. 326:1985;273-280.
184. Uchimura N., Higashi H., Nishi S. Hyperpolarizing and depolarizing actions of dopamine via D-1 and D-2 receptors on nucleus accumbens neurons. Brain Res. 375:1986;368-372.
185. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. 82(Suppl. 367):1971;1-48.
186. Van Bockstaele E.J., Pickel V.M. Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamien afferents. J. Comp. Neurol. 334:1993;603-617.
187. VanderMaelen C.P., Aghajanian G.K. Intracellular studies showing modulation of facial motoneuron excitability by serotonin. Nature (Lond.). 287:1980;346-347.
188. Van Wijngaarden I., Tulp M.Th.M., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188:1990;301-312.
189. Vertes R.P. A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J. Comp. Neurol. 313:1991;643-668.
190. Voigt M.M., Laurie D.J., Seeburg P.H., Bach A. Molecular cloning and characterization of a rat brain cDNA encoding a 5-hydroxytryptamine 1B receptor. EMBO J. 10:1991;4017-4023.
191. Voorn P., Gerfen C.R., Groenewegen H.J. Compartmental organization of the ventral striatum of the rat: immunohistochemical distribution of enkephalin, substance P, dopamine and calcium-binding protein. J. Comp. Neurol. 289:1989;189-201.
192. Walaas I. Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. Neuroscience. 3:1981;399-405.
193. Wang M.Y., Dun N.J. 5-Hydroxytryptamine responses in neonate rat motoneurones in vitro. J. Physiol. (Lond.). 430:1990;87-103.
194. Wang S.S., Ricaurte G.A., Peroutka S.J. [3H]3,4-Methylenedioxymethamphetamine (MDMA) interactions with brain membranes and glass fiber filter paper. Eur. J. Pharmacol. 138:1987;439-443.
195. White F.J. Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions. Pharmacol. Biochem. Behav. 24:1986;365-379.
196. White S.R., Fung S.J. Serotonin depolarizes cat spinal motoneurons in situ and decreases motoneuron after-hyperpolarizing potentials. Brain Res. 502:1989;205-213.
197. White S.R., Neuman R.S. Facilitation of spinal motoneuron excitability by 5-hydroxytryptamine and noradrenaline. Brain Res. 188:1980;119-127.
198. White F.J., Wang R.Y. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons. Brain Res. 300:1984;161-166.
199. 2 dopamine receptors in the rat nucleus accumbens. J. Neurosci. 6:1986;274-280.
200. White, S.R., Fung, S.J. and Barnes, C.D. (1991) Norepinephrine effects on spinal motoneurons. In: The Neurobiology of the Locus Coeruleus. Progress in Brain Research, pp. 343-350. Eds C.D. Barnes and O. Pompeiano. Elsevier: Amsterdam.
201. White S.R., Duffy P., Kalivas P.W. Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens in vivo. Neuroscience. 62:1994;41-50.
202. White S.R., Harris G.C., Imel K.M., Wheaton M.J. Inhibitory effects of dopamine and methylenedioxymethamphetamine (MDMA) on glutamate-evoked firing of nucleus accumbens and caudate/putamen cells are enhanced following cocaine self-administration. Brain Res. 681:1995;167-176.
203. White S.R., Imel K.M., Obradovic T. Long-term attenuation of inhibitory effects of serotonin and dopamine on glutamate-evoked firing of nucleus accumbens cells following repeated injections of methylenedioxymethamphetamine (MDMA). Soc. Neurosci. Abstr. 21:1995;969.
204. Wilson M.A., Ricaurte G.A., Molliver M.E. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience. 28:1989;121-137.
205. Wilson, M.A., Mamounas, L.A., Fasman, K.H., Axt, K.J. and Molliver, M.E. (1993) Reactions of 5-HT neurons to drugs of abuse: Neurotoxicity and plasticity, In: National Institute on Drug Abuse Research Monograph 136, Assessing Neurotoxicity of Drugs of Abuse, pp. 155-186. Ed. L. Erinoff. NIH:
206. Wise R.A., Bozarth M.A. Brain reward circuitry: four circuit elements "wired" in apparent series. Brain Res. Bull. 12:1984;203-208.
207. Woodruff G.N., McCarthy P.S., Walker R.J. Studies on the pharmacology of neurones in the nucleus accumbens of the rat. Brain Res. 115:1976;233-242.
208. Wotherspoon G., Savery D., Priestley J.V., Rattray M. Repeated administration of MDMA down-regulates preprocholecystokinin mRNA expression but not tyrosine hydroxylase mRNA expression in neurones of the rat substantia nigra. Mol. Brain Res. 25:1994;34-40.
209. Wright C.I., Groenewegen J.J. Patterns of convergence and segregation in the medial nucleus accumbens of the rat: relationships of prefrontal cortical, midline thalamic, and basal amygdaloid afferents. J. Comp. Neurol. 361:1995;383-403.
210. Yamamoto B.K., Spanos L.J. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur. J. Pharmacol. 148:1988;195-203.
211. Yamamoto B.K., Nash J.F., Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and γ-aminobutyric acid in the substantia nigra. J. Pharmacol. Expl Ther. 273:1995;1063-1070.
212. Yau J.L.W., Kelly P.A.T., Sharkey J., Seckl J.R. Chronic 3,4-methylenedioxy-methamphetamine administration decreases glucocorticoid and mineralocorticoid receptor, but increases 5-hydroxytryptamine 1C receptor gene expression in the rat hippocampus. Neuroscience. 61:1994;31-40.
213. Yim C.Y., Mogenson G.J. Responses of nucleus accumbens neurons to amygdala stimulation and its modification by dopamine. Brain Res. 239:1982;401-415.
214. Yim C.Y., Mogenson G.J. Neuromodulatory action of dopamine in the nucleus accumbens: an in vivo intracellular study. Neuroscience. 26:1988;403-415.
215. Yoshimoto K., McBride W.J., Lumeng L., Li T.-K. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol. 9:1991;17-22.
216. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience. 65:1995;709-730.
217. Zahm D.S., Brog J.S. Commentary: on the significance of sub-territories in the "accumbens" part of the rat ventral striatum. Neuroscience. 50:1992;751-767.
218. Zahm D.S., Heimer L. Specificity in the efferent projections of the nucleus accumbens in the rat: comparison of the rostral pole projection patterns with those of the core and shell. J. Comp. Neurol. 327:1993;220-232.
219. Zarbin M.A., Innis R.B., Wamsley J.K., Snyder S.H., Huhar M.J. Autoradiographic localization of cholecystokinin receptors in rodent brain. J. Neurosci. 3:1983;877-906.
220. Zito K.A., Vickers G., Roberts D.C.S. Disruption of cocaine and heroin self-administration following kainic acid lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 23:1985;1029-1036.